Trial Profile
A study of IV RP-323 in patients with myelocytic leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Apr 2018
Price :
$35
*
At a glance
- Drugs Tetradecanoylphorbol acetate (Primary)
- Indications Myeloid leukaemia
- Focus Adverse reactions
- 11 Apr 2018 New trial record